You are here

Article Text

Article menu
Download PDFPDF
Original article
Hydrofluoroalkane-beclomethasone versus chlorofluorocarbon-beclomethasone delivery in neonatal models
  1. C H Cole1,
  2. J P Mitchell2,
  3. M P Foley2,
  4. M W Nagel2
  1. 1The Floating Hospital for Children, Tufts-New England Medical Center, Tufts University School of Medicine, Boston, MA, 02111, USA
  2. 2Trudell Medical International, London, Ontario, Canada, N5V 5G4
  1. Correspondence to:
    Dr Cole
    Department of Neonatology, Beth Israel Deaconess Medical Center, 330 Brookline Ave, Boston, MA 02115, USA; ccolebidmc.harvard.edu

Abstract

Dose delivery of hydrofluoroalkane-beclomethasone and chlorofluorocarbon-beclomethasone was compared during in vitro neonatal simulations: mechanical ventilation with 40% and 100% relative humidity + Neonatal Chamber-Ventilator System/endotracheal tube; manual ventilation + Neonatal Chamber/endotracheal tube; “spontaneous breathing” + Neonatal Chamber/face mask without/with manual assistance. The delivery of hydrofluoroalkane-beclomethasone was significantly greater in each simulation.

  • CFC-BDP, chlorofluorocarbon-beclomethasone dipropionate
  • HFA-BDP, hydrofluoroalkane-beclomethasone dipropionate
  • aerosol therapy
  • inhalants
  • glucocorticoid
  • bronchopulmonary dysplasia

https://doi.org/10.1136/adc.2002.022905

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    View Full Text

    Footnotes

    • Disclosure: The manufacturer of chlorofluorocarbon-beclomethasone dipropionate (CFC-BDP; 50 µg/dose; Vanceril50) is Schering, Canada Inc. The manufacturer of hydrofluoroalkane-beclomethasone dipropionate (HFA-BDP; 50 μg/dose; QVAR50) is 3M Pharmaceuticals (Canada). The manufacturer of the two holding chambers (Neonatal Chamber-Ventilator System and Neonatal Chamber) is Trudell Medical International, London, ON, Canada. Trudell Medical International employs all co-authors, except for CHC. In vitro assays were conducted in the medical aerosol laboratory of Trudell Medical International. CHC has no financial arrangements and no conflict of interest with Trudell Medical International, Schering, Canada, or 3M Pharmaceuticals (Canada). CHC and biostatisticians of Tufts University, School of Medicine analysed the data objectively and free of bias by collaborators and co-authors of Trudell Medical International. Trudell Medical International provided financial support for this investigator initiated research.